BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 24, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
BioWorld Science, Cancer RSS Feed RSS

Cancer

Flindr Therapeutics identifies RNF31 inhibitors

July 23, 2025
E3 ubiquitin-protein ligase RNF31 inhibitors are disclosed in a Flindr Therapeutics BV patent as potentially useful for the treatment of cancer.
Read More
Cancer

Shanghai Yuyao Biotech discovers new STAT3 inhibitors

July 23, 2025
Shanghai Yuyao Biotech Ltd. has identified new signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

POLθ inhibitors reported in Breakpoint Therapeutics patents

July 23, 2025
Breakpoint Therapeutics GmbH patents describe new DNA polymerase θ (POLQ, POLθ) inhibitors potentially useful for the treatment of cancer.
Read More
3D rendering of drug linked to antibody
Immuno-oncology

Tubulis’ next-generation ADC shows durable response, enhanced tolerability

July 23, 2025
No Comments
The sodium-dependent phosphate transport protein 2b (NaPi2b), encoded by the SLC34A2 gene, is highly overexpressed in high-grade epithelial ovarian cancer and non-small-cell lung cancer while exhibiting minimal expression in normal adult tissues, making it a relevant tumor-associated antigen and a promising target for antibody-drug conjugates (ADCs).
Read More
Concept art for damaged DNA structure
Cancer

Rakovina makes progress on ATR inhibitor program

July 23, 2025
No Comments
Rakovina Therapeutics Inc. has reported progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (ataxia telangiectasia and Rad3-related) inhibitors designed to disrupt the DNA damage response (DDR) pathway in cancer cells. Through its collaboration with Variational AI Inc., Rakovina has evaluated a vast chemical space of potential molecular structures using Variational’s AI Enki platform to identify novel compounds
Read More
Cancer

Suzhou Genhouse Bio discloses WRN inhibitors for cancer

July 22, 2025
Work at Suzhou Genhouse Bio Co. Ltd. has led to the identification of Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Read More
Drug R&D concept image.
Cancer

Novel CDK9 inhibitor exhibits high selectivity and favorable safety profile

July 22, 2025
No Comments
Cyclin-dependent kinase 9 (CDK9) plays a critical role in regulating transcriptional elongation and is essential for the expression of short-lived oncogenic and antiapoptotic mRNAs. Targeting CDK9 has emerged as a promising therapeutic strategy, particularly in hematological malignancies and MYC-driven cancers. However, its clinical application remains limited by several challenges, which may be overcome through the development of more selective and potent inhibitors.
Read More
Blue cancer cell
Cancer

Research uncovers how USP15 facilitates immune evasion in colorectal cancer

July 22, 2025
No Comments
Colorectal cancer remains a prevalent and deadly form of cancer. A significant challenge to treating colorectal tumors is the creation of a suppressive tumor immune microenvironment that leads to tumor progression and resistance to immunotherapy.
Read More
3d illustration of ovarian cancer
Cancer

G-quadruplexes drive transcriptional reprogramming linked to drug resistance in ovarian cancer cells

July 22, 2025
No Comments
Cancer cells often use epigenetic changes to resist treatment, a major factor particularly in late-stage deaths from ovarian cancer. One potential epigenetic marker, DNA secondary structures known as G-quadruplexes (G4s), has recently gained attention; however, their presence and role in ovarian cancer had not been studied until now.
Read More
Colorectal cancer illustration
Cancer

tRF-3021a impairs NK cell function via MICA cleavage, promoting immune escape in colorectal cancer

July 22, 2025
No Comments
Immune evasion continues to limit the effectiveness of cancer immunotherapies. Among emerging regulatory molecules, transfer RNA-derived small RNAs (tsRNAs of 13-48 nucleotides), generated through tRNA cleavage, are gaining attention for their roles in controlling gene expression at both the transcriptional and translational levels. Recent research suggests that abnormal tsRNA expression is closely associated with the development and progression of colorectal cancer.
Read More
Previous 1 2 … 123 124 125 126 127 128 129 130 131 … 3697 3698 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • Roche reports new TREM2 agonists

    BioWorld Science
    F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
  • Genescience presents STAT6 degrader for atopic dermatitis

    BioWorld Science
    Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing